The Effectiveness of EU Research and Innovation Proposals
Total Page：16
File Type：pdf, Size：1020Kb
European Union Internal Market, Infrastructure and Employment Sub-Committee The Effectiveness of EU Research and Innovation Proposals Oral and written evidence Contents Aberystwyth University (AU)—Written evidence ............................................................................ 3 ADS (Aerospace, Defence, Security and Space)—Written evidence ............................................ 6 Agricultural Biotechnology Council—Written evidence ................................................................ 12 Airbus, EADS, Rolls-Royce, and Pfizer—Oral evidence (QQ 36–53) ......................................... 15 Professor Richard Brook, AIRTO, Professor Mary Ritter, Climate-KIC and John Hill, Growth Accelerator—Oral evidence (QQ 15–35) ......................................................................... 29 Association of the British Pharmaceutical Industry—Written evidence ..................................... 30 The Association of Independent Research and Technology Organisations (AIRTO) — Written evidence ..................................................................................................................................... 34 Association of Medical Research Charities—Written evidence ................................................... 41 Professor Roberto Bernabei, Professor Iain Carpenter, and Bridget Carpenter—Written evidence ..................................................................................................................................................... 46 British Academy—Written evidence .................................................................................................. 51 Department for Business, Innovation and Skills—Written evidence........................................... 54 Rt Hon David Willetts MP, Minister for Universities and Science, Department for Business, Innovation and Skills—Oral evidence (QQ 68–82) ......................................................................... 64 Department for Business, Innovation and Skills—Supplementary written evidence ............... 77 Bridget Carpenter, Professor Roberto Bernabei, and Professor Iain Carpenter—Written evidence ..................................................................................................................................................... 85 Professor Iain Carpenter, Professor Roberto Bernabei, and Bridget Carpenter—Written evidence ..................................................................................................................................................... 86 Professor Christopher Chapple Professor Sheila MacNeil—Written evidence ....................... 87 Chemistry Innovation Limited—Written evidence ......................................................................... 93 Professor Mary Ritter, Climate-KIC, Professor Richard Brook, AIRTO and John Hill, Growth Accelerator—Oral evidence (QQ 15–35) ......................................................................... 96 DARPA (Defense Advanced Research Projects Agency)—Written evidence ........................ 118 Design Wales and RAND Europe—Oral evidence (QQ 54–67) ............................................... 119 EADS UK and Airbus—Written evidence ....................................................................................... 120 EADS, Airbus, Rolls-Royce, and Pfizer—Oral evidence (QQ 36–53) ....................................... 130 EURADIA, the Alliance for European Diabetes Research—Written evidence ...................... 131 European Commission—Written evidence..................................................................................... 137 1 European Molecular Biology Laboratory – European Bioinformatics Institute (EMBL-EBI)— Written evidence ................................................................................................................................... 147 Professor JCT Fairbank, MA, MD, FRCS, Dr Jill Urban, PhD, and Professor Sally Roberts, PhD—Written evidence ...................................................................................................................... 152 The Federation of Small Businesses—Written evidence .............................................................. 153 Vicky Ford MEP—Written evidence ................................................................................................. 154 Dr Michael Galsworthy, PhD and Professor Martin McKee CBE MD DSc MSc FRCP FRCPE FRCPI FFPH FMedSci—Written evidence ....................................................................................... 156 Growth Accelerator—Written evidence ........................................................................................ 163 John Hill, Growth Accelerator, Professor Richard Brook, AIRTO and Professor Mary Ritter, Climate-KIC—Oral evidence (QQ 15–35) ..................................................................................... 170 Growth Accelerator—Supplementary written evidence ............................................................. 171 Malcolm Harbour CBE MEP—Oral evidence (QQ 1–14) ........................................................... 173 Institute of Physics—Written evidence ............................................................................................ 186 LCA Europe Limited—Written evidence ........................................................................................ 190 Professor Sheila MacNeil and Professor Christopher Chapple—Written evidence ............. 195 Professor Martin McKee CBE MD DSc MSc FRCP FRCPE FRCPI FFPH FMedSci and Dr Michael Galsworthy, PhD—Written evidence ............................................................................... 196 Microsoft—Written evidence ............................................................................................................. 197 Gavin Cawood, National Centre for Product Design + Development Research (PDR) and Design Wales—Written evidence ..................................................................................................... 200 National Institute for Health Research Evaluation, Trials and Studies Coordinating Centre (NETSCC)—Written evidence .......................................................................................................... 205 Open University—Written evidence ................................................................................................ 208 Pfizer, Rolls-Royce, EADS, and Airbus—Oral evidence (QQ 36–53) ....................................... 211 Dr Adam Heathfield Senior Director, Worldwide Policy, Pfizer—Supplementary written evidence ................................................................................................................................................... 212 RAND Europe and Design Wales—Oral evidence (QQ 54–67) ............................................... 214 Research Councils UK (RCUK)—Written evidence .................................................................... 228 Professor Sally Roberts, PhD, Dr Jill Urban, PhD, and Professor JCT Fairbank, MA, MD, FRCS—Written evidence .................................................................................................................... 233 Rolls-Royce, EADS, Airbus, and Pfizer—Oral evidence (QQ 36–53) ....................................... 234 Royal Society of Chemistry—Written evidence ............................................................................ 235 The Russell Group of Universities—Written evidence ................................................................ 237 The Society of Motor Manufacturers and Traders—Written evidence ................................... 242 University College London—Written evidence ............................................................................. 244 Universities UK and the UK HE International Unit—Written evidence .................................. 246 Dr Jill Urban, PhD, Professor JCT Fairbank, MA, MD, FRCS, and Professor Sally Roberts, PhD—Written evidence ...................................................................................................................... 251 The Wellcome Trust—Written evidence ....................................................................................... 253 2 Aberystwyth University (AU)—Written evidence Aberystwyth University (AU)—Written evidence Comments from Aberystwyth University (AU) on the proposals for Horizon 2020 1 Introduction Aberystwyth University (AU) broadly welcomes the proposals for Horizon 2020 proposals as they offer an excellent opportunity to streamline the ‘innovation cycle’, and so increase Europe and Wales’ competitiveness. Being based within a convergence area, AU welcomes the proposals in that research and innovation funding remain separate, but complementary with cohesion policies and instruments. 2.0 Potentially positive aspects of proposals for Horizon 2020 that AU recommends should be retained 2.1 EU support, particularly to Marie Curie Actions and European Research Centre grants, are likely to continue in Horizon 2020. These are helpful in drawing-in exceptional researchers from across the world into Wales, creating new highly skilled jobs, and generating research that can then be utilised in wealth creation. The proposed budget increase of 77% to support the European Research Council is welcomed. 2.2 The involvement with the FP7 Collaboration projects in particular benefits AU in many ways including raising the organisation’s profile as a world-class research institution, allowing research peers from